CD86 and neoplasm: Exposure of DCs to the 33% Cu-doped TiO2 NPs resulted in higher levels of MHCII, as was also observed for DCs in the tumor-draining lymph nodes, insignificantly affected activation markers CD80 or CD86 (Fig. 6A–C).